This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ENZAMET was a randomized phase 3 treatment trial evaluating enzalutamide in combination with androgen deprivation therapy for patients with metastatic prostate cancer.
| Feature | ENZAMET |
|---|---|
| Condition | Prostatic Neoplasms |
| Intervention | Enzalutamide; NSAA; LHRHA or Surgical Castration |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment | Sponsor | University of Sydney |
| ClinicalTrials.gov | NCT02446405 |
2. Clinical Question
Population
Patients with metastatic prostate cancer.
Intervention
Enzalutamide with androgen deprivation therapy.
Comparator
NSAA with LHRHA or Surgical Castration.
Primary question
Whether enzalutamide as first-line androgen deprivation therapy improves overall survival time.
3. Trial Design
Randomize
1125 patients
Treatment
Two arms
Follow-up
Time-to-event assessment
Endpoint
Overall survival
Analysis
Planned evaluation
Enzalutamide arm
Enzalutamide combined with androgen deprivation therapy.
Control arm
NSAA with LHRHA or Surgical Castration.
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Overall Survival Time | The interval from the date of randomisation to date of death. | 3 years |
5. Planned Analysis
The ClinicalTrials.gov record identifies Overall Survival Time as the primary endpoint. This is a time-to-event endpoint, typically evaluated using methods that account for censoring, such as Kaplan-Meier estimation, survival comparisons between randomized groups, and regression models for relative treatment effects.
6. Statistical Methodology
Time-to-event analysis
Overall survival measures the time from randomisation until death. Unlike simple binary outcomes, survival analysis incorporates patients who have not yet experienced the event at the time of analysis through censoring.
The Kaplan-Meier estimator summarizes observed survival over follow-up while accounting for censored observations.
Hazard-based comparisons
Randomized oncology trials commonly compare treatment groups using hazard-based methods. A hazard ratio summarizes the relative event rate over the analyzed follow-up period, but it is not the same as a risk ratio or difference in survival percentages.
7. Statistical Methods Explained
Why is overall survival a time-to-event endpoint?
Because patients may experience different follow-up durations, survival analysis allows information from all available observation times to contribute to the comparison.
What does censoring mean?
Censoring occurs when a patient's exact event time is not observed during the analysis period. The available follow-up remains informative up to the censoring time.
Why is randomization important?
Randomization creates treatment groups that can be compared without relying on observed differences between patient characteristics.
Why would Kaplan-Meier methods be used?
Kaplan-Meier estimation is designed for outcomes where events occur over time and some observations are incomplete.
Why might a Cox model be used?
A Cox proportional-hazards model can estimate a relative treatment effect while accounting for follow-up time and censoring.
8. Limitations
- No posted statistical analyses: the registry does not report formal statistical analyses or numerical efficacy results.
- Endpoint interpretation: overall survival depends on follow-up duration and event accumulation.
- Censoring: incomplete follow-up requires assumptions inherent to survival methods.
- Generalizability: interpretation depends on the enrolled population and trial eligibility criteria.
- Future updates: additional registry updates may provide further statistical information.
9. Why This Trial Matters Statistically
ENZAMET is a useful example for understanding modern randomized oncology trial methodology. The study illustrates how treatment comparisons in metastatic cancer often rely on time-to-event endpoints rather than simple proportions.
| Concept | Application |
|---|---|
| Randomization | Parallel randomized treatment comparison |
| Survival analysis | Primary endpoint based on time from randomisation to death |
| Censoring | Important feature of long-term follow-up |
| Hazard models | Common framework for treatment-effect estimation |